Back to Authors

Johnson, Steven T.

https://orcid.org/0000-0001-7078-2093

Mayo Clinic

Corewell Health

Citations 2

Clinical Pharmacists and Industry: Guidelines for Professional Interactions
Irwin, Adriane N. , Spinler, Sarah A. , Baye, Jordan , Byerley, Summer Danielle, Evans, Emily, Florczykowski, Brittany , Fritz, Megan Kunka , Kawaguchi‐Suzuki, Marina, Johnson, Steven T. , Raheem, Farah , Rhee, Diane, Yogaratnam, Dinesh, Baye, Jordan F , Bulloch, Marilyn N , Byerley, Summer D , Florczykowski, Brittany , Fritz, Megan K , Kawaguchi-Suzuki, Marina , Johnson, Steven T , Raheem, Farah , Saad, Maha , Yogaratnam, Dinesh , Saad, Maha

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | February 20, 2026 | Volume: 9 | Issue: 3 | Pages: No page available

10.1002/jac5.70190 Get It

ABSTRACT Interactions between clinical pharmacists and industry partners continue to evolve as health care increases in complexity and technology assumes a more dominant role. To address the corresponding ethical challenges, the 2025 Industry Relations Committee of the American College of Clinical Pharmacy (ACCP) was charged with updating the 2008 ACCP position statement, Pharmacists and Industry: Guidelines for Ethical Interactions . This update expands its perspective, reflecting the broader and more influential roles pharmacists play across the health care ecosystem. All clinical pharmacist–industry interactions should be grounded in improving patient care. Through this lens, six recommendations are provided: (1) Pharmacists should not engage in industry partnerships or collaborations that might unduly influence objectivity, independence, or fairness in clinical and professional judgments; (2) Pharmacists should disclose and mitigate financial, consulting, or other relationships that constitute potential conflicts of interest and should not participate in activities where an existing conflict cannot be resolved; (3) Pharmacists who participate in industry‐sponsored research should follow accepted ethical, regulatory, and scientific standards; (4) Pharmacists providing continuing education programs or developing drug information materials should maintain control of content; ensure their content is fair, balanced, and free from bias; and disclose and mitigate any conflicts; (5) Formal instruction on ethical interactions with industry professionals should begin early and continue through all stages of pharmacist education, training, and professional development; (6) Pharmacists should maintain the confidentiality and privacy of patients and other health care professionals when working with industry partners. Questions to guide personal industry interactions are provided. This paper does not detail every emerging area (e.g., artificial intelligence, social media), but recommendations are applicable wherever clinical pharmacists leverage their professional expertise. By maintaining a critical, discerning, and ethical approach to industry collaborations, clinical pharmacists can uphold professional obligations while contributing to the advancement of evidence‐based practice, ultimately prioritizing patient welfare.
Responsible Use of Artificial Intelligence in Health Care: Evidence, Challenges, and Best Practices: An Opinion of the Drug Information Practice and Research Network of the American College of Clinical Pharmacy
Abdalla, Maha , Saad, Maha , Abazia, Daniel , Advani, Ashish, Alhammad, Abdullah , Bernknopf, Allison , Bitra, Veera Raghavulu , Blommel, Matthew L. , Goldwire, Micheline Andel , Gosser, Rena , Iso, Tomona , Johnson, Steven T. , Kier, Karen L. , Kostrzewa, Audrey B. , Majerczyk, Daniel , Phillips, Jennifer , Segovia, Miguel , Sibbesen, Julie B. , Sehman, Marina , Sommer, Christine D. , Thornby, Krisy‐Ann , Saad, Maha , Alhammad, Abdullah M , Conn, Kelly M. , Munir, Faria Maisha , Stark, Jennifer E.

JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY | October 27, 2025 | Volume: 8 | Issue: 12 | Pages: 1333-1361

10.1002/jac5.70131 Get It

ABSTRACT As artificial intelligence (AI) continues to rapidly reshape health care, there is a critical need for clear frameworks for clinicians to ensure ethical, equitable, and effective integration and use of AI in patient care. Key integrations of AI include enhancing health communications, patient engagement, clinicians' training, pharmaceutical advertising, clinical decision‐making, and automation of clinical operations and workflow. However, there are growing concerns related to regulatory gaps, the spread of misinformation, security threats, patient and data privacy leaks, and widening health disparities gaps. These concerns are exacerbated by limited institutional infrastructure and limited AI literacy of clinicians and patients. Recent policy developments reflect efforts to guide responsible AI development and use. While progress has been made, the lack of standardized human oversight remains a critical gap, particularly as policies may not fully consider the challenges and complexities at institutional, societal, technical, and individual levels. Thus, herein, the Drug Information Practice and Research Network (DI PRN) of the American College of Clinical Pharmacy (ACCP) : (1) explores current and emerging multifaceted challenges, a call to action, and opportunities of AI integration in health care including examination of the regulatory, ethical, operational, and health equity implications; and (2) provides practical recommendations for responsible use of AI through DI PRN‐developed example case‐based approaches and best practices infographics to enhance AI literacy for diverse learners including clinicians, trainees, and patients. This DI PRN opinion paper highlights the importance of proactive governance frameworks and equips and empowers diverse learners with practical AI literacy tools to confidently engage with AI technologies in patient care.